


Model-Informed Drug Development

**MIDD+**

2021 Virtual Conference



HTPK

A bridge to Early Development

# High-Throughput PK - Vision

- Develop a simplified early PK assessment tool for non DMPK experts
- Provide dose and time-dependent modeling capabilities
- Avoid the need to input experimental values but allow their use if available
- Identify potential development issues as early as possible, even before compounds are synthesized



# Partnered R&D Project

Apr 7, 2020 | Press Release

## Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®

Keywords: [ADMET cheminformatics](#), [drug discovery](#), [HTPK simulation module](#), [PBPK modeling](#) Software:

[ADMET Predictor®](#) Division: [Simulations Plus](#)

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new collaboration agreement with a large pharmaceutical company to advance its [ADMET Predictor®](#) machine learning capabilities for use within integrated drug discovery workflows. With the drugmaker's investment, Simulations Plus will develop enhanced capabilities in its existing [HTPK Simulation Module](#) to incorporate physiologically based pharmacokinetic (PBPK) modeling in its high-throughput drug discovery platform to support compound screening activities.

Sep 29, 2020 | Press Release

## Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®

Keywords: [admet predictor](#), [APX](#), [biopharmaceutical](#), [cheminformatics](#), [collaboration](#), [HTPK simulation module](#), [pharmaceutical](#) Software: [ADMET Predictor®](#) Division: [Simulations Plus](#)



Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into an accelerated second phase of its collaboration with a large pharmaceutical company to tailor its high-throughput pharmacokinetic (HTPK) simulation functionality within [ADMET Predictor®](#) to support the sponsor partner's lead selection activities for small molecule programs.



# HTPK Visualization

Native ADMET Predictor®

Alternate Front End




- Command-line access (Windows + Linux)
- Workflow platforms

- Pipeline Pilot
- KNIME



# HTPK Simulation Model

ACAT™ Model\* + Compartmental Model



\*  
Advanced  
Compartmental  
Absorption and  
Transit Model




# HTPK Simplifications

- Gut clearance is not considered
- Passive absorption kinetics only (paracellular included)
- Clearance is assumed to follow linear kinetics
- Enterohepatic circulation and biliary excretion not considered
- First-order precipitation kinetics assumed
- Dosage form is IR tablet – IV Bolus in next release
- Physiology limited to fasted adult human or rat





# HTPK Predictions (APX)



# HTPK Input Parameters

Simulate fraction absorbed and bioavailable

Process status:

Species:  Rat  Human

Dose(s) [mg]: 1.0;10.0;100.0

% Absorbed Prefix: %Fa\_hum-

% Bioavailable Prefix: %Fb\_hum-

Clearance parameter

Type: Liver microsomes uL/min/mg HLM

Preferred value: CYP\_HLM\_CLint  Unbound

Fallback value: CYP\_HLM\_CLint  Unbound

Buttons: Minimize, Advanced, Save, Run, Cancel

Advanced simulation parameters

Species: Human

logP  logD S+logP

at pH

Solubility [mg/mL] S+Sw

at pH S+pH\_Satd

Solubility factor SolFactor

Permeability [cm/s \* 10<sup>4</sup>] S+Peff

Unbound in plasma [%] hum\_fup%

Blood to plasma ratio RBP

Volume of distribution [L/kg] Vd

First-pass extraction [%] <Mechanistic>

Dosing interval [h]

Buttons: OK, Cancel


Inputs can be experimental values or predictions

Predicted inputs can be from ADMET Predictor or your own models

Configuration files contain additional parameters (e.g., particle size)



# Comparison with GastroPlus®



100 compounds  
Approved drugs

Time in GP  
A few min...

Time in AP  
...Under a sec



# HTPK Performance



- Calculation of %Fa and %Fb in human after 24h.

Three different dose levels:

- 1 mg **10,560 diverse compounds from Enamine Diversity Set**
- 10 mg
  - AP 9.5: 7min. 31 sec (23 cmpds/sec)
- 100 mg
  - APX with multithreading (7 threads): 1min 30 sec (117 cmpds/sec)

DELL Vostro Laptop - Intel® Core™ i7-8550U CPU 1.80 GHz  
4 Cores, 8 Logical Processors - 16 GB RAM, Windows 10 64-bit





# R&D Horizon

Spring 2021

## HTPK Enhancements

- IV Bolus route of administration
- Ability to define non-specific binding
- Ability to define “free” target concentration
- Support use of Ctrough/Cmax in dose optimization
- Enhancements in command line support using .inp and .hia files



# HTPK Webinar

Mark your Calendars: April 7<sup>th</sup>, 2021 at 8:00am PST

Early assessment of PK properties with the ADMET Predictor<sup>®</sup> HTPK Simulation module, a high-throughput mechanistic PBPK approach

Speaker: ?



# Q & A

Questions & Answers

Model-Informed Drug Development

# MIDD+

2021 Virtual Conference



Thank you for your time  
and attention !



Learn More! [www.simulations-plus.com](http://www.simulations-plus.com)

**S+** *SimulationsPlus*

Cognigen | *DILIsym Services* | Lixoft

# HTPK Recent Citations



Vol 140, June 2020

Liver toxicity of anthraquinones: A combined *in vitro* cytotoxicity and *in silico* reverse dosimetry evaluation

Yitong Liu, Mapa S.T. Mapa, Robert L. Sprando

Division of Toxicology, Office of Applied Research and Safety Assessment, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration

